Chinese expert consensus on prevention and treatment of delayed nausea and vomiting (2022 Edition)

Abstract

Abstract Nausea and vomiting are common adverse reactions of antitumor therapy, among which chemotherapy-induced nausea and vomiting (CINV) has been studied most intensively. Because of insufficient prevention or insufficient attention, CINV brings a series of harms to cancer patients and even lead to the delay or termination of antitumor therapy. Delayed CINV is often underestimated because it mostly occurs outside the hospital, and patients cannot report it immediately. In recent years, the proportion of outpatient chemotherapy and day-time chemotherapy patients in China has increased year by year. Therefore, the prevention of delayed CINV is particularly important. Currently, the challenges faced by delayed CINV include the need to deeply explore its physiological and pathological mechanisms, improve its risk assessment standards, and optimize its prevention programs. However, there is still lack of practice guidelines or consensus on delayed CINV. Therefore, the Committee of Neoplastic Supportive-Care of China Anti-Cancer Association organized multidisciplinary experts in this field to formulate this consensus based on the analysis and discussion of current evidence-based medical research in combination with clinical problems that need to be solved urgently.